|
Manufacturing, Supply Chain, and Inspections during the COVID19 Public Health Emergency August 25, 2021 | 9:00 a.m. - 1:00 p.m. Eastern | | |
|
Webinar participants will hear the latest updates from FDA's Center for Drug Evaluation Research (CDER) regarding policy and approaches toward manufacturing, supply chain, and inspections during the COVID19 Public Health Emergency (PHE). TOPICS - FDA guidance on manufacturing during COVID-19 and high absenteeism
- Risk management and application approaches in responding to supply chain constraints during public health emergency
- Inspections and use of alternate tools during the public health emergency
| | AUDIENCE - Quality unit leaders
- Quality and manufacturing personnel
- Regulatory affairs professionals who manufacture drugs for the US market (inclusive of application and non-application products)
| | |
No comments:
Post a Comment